CD33 and acute myeloid leukemia: Additionally, a study on CD33-targeted CAR-T-cell therapy for AML demonstrated a transient reduction in CD33+ leukemic blasts (lasting only 7 days), accompanied by adverse effects such as leukopenia [122].